ClinicalTrials.Veeva

Find clinical trials for Leukemia in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Warszawa, Mazowieckie, POL:

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (...

Active, not recruiting
Acute Myeloid Leukemia
High-risk Myelodysplastic Syndrome
Drug: RVU120(SEL120)

Phase 1

Ryvu Therapeutics

Warsaw, Poland and 9 other locations

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

Warszawa, Mazowieckie, Poland and 85 other locations

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001)

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior m...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Warsaw, Poland and 222 other locations

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...

Active, not recruiting
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Drug: Pevonedistat
Drug: Azacitidine

Phase 3

Takeda
Takeda

Warszawa, Mazowieckie, Poland and 240 other locations

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib versus asciminib 80mg in pre-treated patients with Chronic Myeloid Leukemia...

Active, not recruiting
Chronic Myelogenous Leukemia
Leukemia, Myeloid Chronic
Drug: Asciminib add-on
Drug: Nilotinib

Phase 2

Novartis
Novartis

Warszawa, Poland and 28 other locations

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Venetoclax
Drug: Cusatuzumab

Phase 1

OncoVerity

Warszawa, Poland and 22 other locations

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabin...

Enrolling
Leukemia, Myeloid, Acute
Drug: Liposomal Annamycin
Drug: Cytarabine

Phase 1, Phase 2

Moleculin Biotech

Warsaw, Poland and 8 other locations

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: gilteritinib
Drug: azacitidine

Phase 3

Astellas
Astellas

Warszawa, Mazowieckie, Poland and 110 other locations

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) p...

Active, not recruiting
Chronic Myelogenous Leukemia
Drug: ABL001 200mg QD
Drug: ABL001 40mg BID

Phase 3

Novartis
Novartis

Warszawa, Poland and 47 other locations

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

in children with relapsed or refractory acute lymphoblastic leukemia (ALL).Determine the maximum tolerated dose (MTD) and to recommend a pha...

Active, not recruiting
Acute Lymphoblastic Leukemia (ALL)
Drug: Vincristine
Drug: Intrathecal (IT) Methotrexate

Phase 1

Amgen
Amgen

Warszawa, Poland and 122 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems